n-Hydroxynaphthalimides are a class of heterocyclic compounds that have garnered significant interest in various scientific fields due to their diverse pharmacological properties. They exhibit fluorescence, making them suitable for applications in imaging and sensing. Notably, their ability to act as potent inhibitors of kinases and other enzymes has spurred research into their potential as therapeutic agents. The synthesis of n-hydroxynaphthalimides typically involves a multi-step process that begins with the condensation of a naphthalic anhydride with an amine, followed by a hydroxylation reaction. Research into n-hydroxynaphthalimides focuses on understanding their structure-activity relationships, optimizing their synthesis, and exploring their applications in various fields such as cancer therapy, drug discovery, and materials science.'
N-hydroxynaphthalimide: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 82263 |
| CHEMBL ID | 1207029 |
| SCHEMBL ID | 132760 |
| MeSH ID | M0503759 |
| Synonym |
|---|
| OPREA1_347699 |
| {1h-benz[de]isoquinoline-1,3(2h)-dione,} 2-hydroxy- |
| 2-hydroxybenzo[de]isoquinoline-1,3-dione |
| 2-hydroxy-1h-benzo[de]isoquinoline-1,3(2h)-dione |
| OPREA1_199438 |
| 7797-81-1 |
| nsc-108691 |
| n-hydroxy-1,8-naphthalimide |
| naphthalimide, n-hydroxy- |
| n-hydroxynaphthalimide |
| naphthalhydroxamic acid |
| 1h-benz[de]isoquinoline-1, 2-hydroxy- |
| nsc108691 |
| NCI60_000204 |
| bdbm50121921 |
| chembl1207029 , |
| AKOS000592473 |
| 2-hydroxy-1h-benz(de)isoquinoline-1,3(2h)-dione |
| HMS1608O06 |
| H1040 |
| n-hydroxy-1,8-naphthalenedicarboximide |
| A839302 |
| STK982003 |
| unii-dzg9avw5v2 |
| dzg9avw5v2 , |
| 1h-benz(de)isoquinoline-1,3(2h)-dione, 2-hydroxy- |
| einecs 232-251-9 |
| nsc 108691 |
| FT-0636601 |
| 1h-benz[de]isoquinoline-1,3(2h)-dione, 2-hydroxy- |
| F0020-1889 |
| SCHEMBL132760 |
| BBL028101 |
| 2-hydroxy-1h-benz[de]isoquinoline-1,3(2h)-dione |
| DTXSID0064884 |
| naphthal hydroxamic acid |
| 2-hydroxy-1h-benzo[de]isoquinoline-1,3(2h)-dione # |
| sr-01000400058 |
| SR-01000400058-1 |
| mfcd00065062 |
| VS-08666 |
| 3-hydroxy-3-azatricyclo[7.3.1.0?,(1)(3)]trideca-1(13),5,7,9,11-pentaene-2,4-dione |
| AMY37429 |
| D82011 |
| CS-0155692 |
| SY057409 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Flap endonuclease 1 | Homo sapiens (human) | IC50 (µMol) | 0.3000 | 0.0001 | 0.2000 | 0.3000 | AID1247799 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID1247799 | Inhibition of FEN1 (unknown origin) | 2015 | Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19 | N-Hydroxyimides and hydroxypyrimidinones as inhibitors of the DNA repair complex ERCC1-XPF. |
| AID1247798 | Inhibition of ERCC1-XPF (unknown origin) by high-throughput fluorescence based in-vitro endonuclease assay | 2015 | Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19 | N-Hydroxyimides and hydroxypyrimidinones as inhibitors of the DNA repair complex ERCC1-XPF. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.47) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 1 (16.67%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (83.33%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||